Clinical Trial

Efficacy of Intermediate-Dose Cytarabine Induction Regimen in Adult AML

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated May 30, 2025 (before its estimated May 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
In this open-label, randomized, prospective clinical trial, newly-diagnosed AML patients will be randomized into 2 groups. In the experimental arm, patients receive DA induction regimen with intermediate dose of cytarabine. In the control arm, patients receive DA regimen with standard dose of cytarabine.The efficacy of induction therapy containing intermediate dose of cytarabine is evaluated and adverse events associated with treatment are recorded.The primary end point is overall survival.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2017-01-12; most recent amendment 2025-05-26.
Status change: Recruiting → Active, Not Recruiting 2025-05-26
Status change: Not Yet Recruiting → Recruiting 2017-02-28
Trial Details
NCT Number NCT03021330
Lead Sponsor Institute of Hematology & Blood Diseases Hospital, China
Conditions AML
Enrollment 1,100 participants
Start Date 2017-02-08
Primary Completion 2026-05-15 (estimated)
Study Completion 2027-10-15 (estimated)
Updated on ClinicalTrials.gov 2025-05-30